Lupin has settled all its ongoing patent litigation with US-based Forest Laboratories on the Alzheimer’s disease treatment drug, Namenda (memantine tablets). By the settlement, Lupin will be licensed under the relevant patents and would be free to commercially launch its generic product in January, 2015, or earlier in certain circumstances.
Sources said Lupin is believed to be the first to challenge the patent of this drug, which had sales of $949 million in the
Such out-of-court settlements are part of the generic drug business in the
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |